clinical trial · NCT07008417
A Study on Bioequivalence of Cabergoline Tablets in Human Body
Changchun GeneScience Pharmaceutical Co., Ltd.·phase1·active not recruiting·n = 72
HyperprolactinemiaCabergoline tablets test formulationCabergoline tablets reference formulation
brief summary
The purpose of this study is to evaluate the bioequivalence of the test formulation and reference formulation of cabergoline tablets in healthy Chinese subjects under fasting and postprandial conditions.
started
Jun 30, 2025
primary completion
Feb 3, 2026
completion
May 6, 2026
last updated
Nov 17, 2025
official title
A Single-center, Randomized, Open-label, Two-formulation, Two-cycle, Two-sequence, Single-dose, Crossover Bioequivalence Study of Cabergoline Tablets Under Fasting and Postprandial Conditions in Healthy Chinese Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol